Clinical trial
Previously Untreated Advanced Non-Small Cell Lung Cancer (NSCLC)
NCT00254319 · The Cooper Health System, Other · Unknown status
Key facts
| NCT number | NCT00254319 |
|---|---|
| Title | Previously Untreated Advanced Non-Small Cell Lung Cancer (NSCLC) |
| Official title | Phase II Trial of Bevacizumab (Avastin) Plus Pemetrexed (Alimta) and Carboplatin in Previously Untreated Advanced Non-Small Cell Lung Cancer (NSCLC) |
| Lead sponsor | The Cooper Health System, Other |
| Status | Unknown status |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Untreated Advanced Non-Small Cell Lung Cancer |
| Intervention type | Drug |
| Interventions | Avastin, Alimta |
| First posted | Nov 16, 2005 |
| Last update posted | Nov 16, 2005 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- 1–9 FDA inspections linked to this trial
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: